Provided by Tiger Trade Technology Pte. Ltd.

Biogen

225.71
+7.283.33%
Post-market: 225.710.00000.00%19:30 EDT
Volume:815.01K
Turnover:182.78M
Market Cap:33.32B
PE:40.09
High:227.20
Open:220.62
Low:219.23
Close:218.43
52wk High:230.49
52wk Low:138.00
Shares:147.64M
Float Shares:147.31M
Volume Ratio:0.76
T/O Rate:0.55%
Dividend:- -
Dividend Rate:- -
EPS(TTM):5.63
EPS(LYR):8.79
ROE:4.58%
ROA:5.21%
PB:1.77
PE(LYR):25.68

Loading ...

U.S. Stocks on the MOVE -VF Corp, Biogen, AbbVie

Reuters
·
6 hours ago

UBS Lifts Biogen PT on Late-Stage Pipeline Catalysts; Shares Rise

Reuters
·
8 hours ago

Biogen Price Target Raised to $270.00/Share from $240.00 by UBS

Dow Jones
·
Yesterday

Pharma Stocks Jump With Novavax up 12%, Moderna up 6%

Tiger Newspress
·
Yesterday

UBS Adjusts Price Target on Biogen to $270 From $240, Maintains Buy Rating

MT Newswires Live
·
Yesterday

Biogen price target raised to $270 from $240 at UBS

TIPRANKS
·
Yesterday

Biogen Inc. Stock Underperforms Thursday When Compared to Competitors

Dow Jones
·
Yesterday

Biogen Price Target Cut to $256.00/Share from $260.00 by RBC Capital

Dow Jones
·
Oct 08

RBC Cuts Price Target on Biogen to $256 From $260, Keeps Outperform Rating

MT Newswires Live
·
Oct 08

Biogen : RBC Cuts Target Price to $256 from $260

THOMSON REUTERS
·
Oct 08

How Positive Lupus Trial Data Will Impact Biogen Stock (BIIB)

Simply Wall St.
·
Oct 08

Pharma Stocks Rally With Amgen, Gilead Sciences up 3%

Tiger Newspress
·
Oct 07

AI Predicted Novartis’ $30 Billion Drug Failure. Are Biogen and Takeda Next?

TIPRANKS
·
Oct 07

Why Vaxcyte Chose A 1.5% Convertible

Macro World​
·
Oct 07

Biogen Maintained at Buy as Analyst Sees Favorable Risk-Reward Ahead of Lupus Data; $256 Price Target Reaffirmed

TIPRANKS
·
Oct 06

From Lilly Deal to Market Darling: Inside Ginkgo's 120% Monthly Run

Bellwether Stocks Movement
·
Oct 06

Biogen Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Oct 06

Piper Sandler Keeps Their Buy Rating on Biogen (BIIB)

TIPRANKS
·
Oct 05

One Molecule, Three Diseases, $1.55 Billion — Inside CSL's Bet

Bellwether Stocks Movement
·
Oct 05

Merck Doubled Off Its Lows — And Analysts Still See More Room

Bellwether Stocks Movement
·
Oct 05